Clinical Trial Update: Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing palbociclib in combination with anti-HER2 therapy for triple-positive breast cancer is ongoing, with status not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasm

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Breast Neoplasm Female | Phase 2 | Status: UNKNOWN